Symbols / ASND Stock $218.84 +0.95% Ascendis Pharma A/S
ASND (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteAscendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-19 | init | Citigroup | — → Buy | $355 |
| 2026-05-15 | main | Evercore ISI Group | Outperform → Outperform | $329 |
| 2026-05-11 | main | Barclays | Overweight → Overweight | $345 |
| 2026-05-08 | main | Wells Fargo | Overweight → Overweight | $326 |
| 2026-04-16 | main | B of A Securities | Buy → Buy | $292 |
| 2026-04-09 | reit | Wedbush | Outperform → Outperform | $273 |
| 2026-03-03 | main | RBC Capital | Outperform → Outperform | $275 |
| 2026-02-12 | main | Oppenheimer | Outperform → Outperform | $262 |
| 2026-02-12 | main | Wedbush | Outperform → Outperform | $273 |
| 2026-01-30 | main | B of A Securities | Buy → Buy | $260 |
| 2026-01-28 | init | Barclays | — → Overweight | $342 |
| 2026-01-20 | main | RBC Capital | Outperform → Outperform | $250 |
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $330 |
| 2026-01-09 | main | Wells Fargo | Overweight → Overweight | $322 |
| 2026-01-07 | reit | TD Cowen | Buy → Buy | $325 |
| 2025-12-11 | main | Stifel | Buy → Buy | $256 |
| 2025-11-18 | reit | Wedbush | Outperform → Outperform | $220 |
| 2025-10-17 | init | Raymond James | — → Strong Buy | $271 |
| 2025-10-13 | main | Cantor Fitzgerald | Overweight → Overweight | $254 |
| 2025-10-09 | main | JP Morgan | Overweight → Overweight | $264 |
- Insider Purchase: EVP & Chief Financial Officer of $ASND Buys 100 Shares - Quiver Quantitative ue, 02 Jun 2026 20
- Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy - Stock Titan ue, 02 Jun 2026 20
- Ascendis Pharma A/S (ASND) Stock Analysis: A 33% Upside Potential In The Biotech Sector - DirectorsTalk Interviews Mon, 01 Jun 2026 09
- (ASND) Movement as an Input in Quant Signal Sets - Stock Traders Daily ue, 02 Jun 2026 18
- Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq - Yahoo Finance Sun, 12 Apr 2026 07
- Ascendis Pharma (ASND) director adds 500 shares in open-market buys - Stock Titan Mon, 01 Jun 2026 20
- Insider Buying: Scott Smith Acquires Additional Shares of Ascendis Pharma AS (ASND) - GuruFocus ue, 02 Jun 2026 22
- ASND - Ascendis Pharma A/S Stock Price and Quote - Finviz ue, 26 May 2026 10
- Ascendis Pharma slides 5.6% as investors digest recent run-up; no single headline catalyst apparent - Quiver Quantitative Fri, 29 May 2026 21
- Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance Fri, 15 May 2026 07
- Ascendis Pharma (NASDAQ: ASND) CFO details shares, RSUs and warrant stakes - Stock Titan Mon, 01 Jun 2026 20
- Ascendis Pharma A/S (ASND) Stock Analysis: Impressive Revenue Growth and Strong Buy Ratings Signal a Promising Future - DirectorsTalk Interviews Mon, 18 May 2026 07
- Has Ascendis Pharma (ASND) Share Price Outpaced Its Fundamentals After Pipeline Progress News - Yahoo Finance Fri, 06 Feb 2026 08
- Ascendis Pharma (ASND) CFO makes open-market buy of 250 shares - Stock Titan Mon, 01 Jun 2026 20
- Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum - Yahoo Finance Sun, 25 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
720.13
+98.03%
|
363.64
+36.34%
|
266.72
+421.20%
|
51.17
|
| Operating Revenue |
|
720.13
+98.03%
|
363.64
+36.34%
|
266.72
+421.20%
|
51.17
|
| Cost Of Revenue |
|
94.92
+114.46%
|
44.26
-0.31%
|
44.40
+265.78%
|
12.14
|
| Reconciled Cost Of Revenue |
|
87.04
+159.01%
|
33.61
-24.30%
|
44.40
+265.78%
|
12.14
|
| Gross Profit |
|
625.22
+95.76%
|
319.38
+43.66%
|
222.32
+469.52%
|
39.04
|
| Operating Expense |
|
761.49
+27.31%
|
598.15
-11.76%
|
677.86
+12.82%
|
600.85
|
| Research And Development |
|
303.62
-1.10%
|
307.00
-25.75%
|
413.45
+8.91%
|
379.62
|
| Selling General And Administration |
|
448.04
+57.72%
|
284.08
+7.44%
|
264.41
+22.50%
|
215.85
|
| General And Administrative Expense |
|
448.04
+57.72%
|
284.08
+9.77%
|
258.79
+19.89%
|
215.85
|
| Salaries And Wages |
|
210.42
+45.94%
|
144.18
+24.61%
|
115.71
+23.12%
|
93.98
|
| Other Gand A |
|
237.63
+69.86%
|
139.90
-2.22%
|
143.08
+17.41%
|
121.87
|
| Total Expenses |
|
856.40
+33.31%
|
642.40
-11.06%
|
722.26
+17.83%
|
612.99
|
| Operating Income |
|
-136.27
+51.12%
|
-278.76
+38.81%
|
-455.54
+18.92%
|
-561.81
|
| Total Operating Income As Reported |
|
-136.27
+51.12%
|
-278.76
+38.81%
|
-455.54
+18.92%
|
-561.81
|
| EBITDA |
|
-114.31
+60.59%
|
-290.02
+29.46%
|
-411.17
+22.30%
|
-529.18
|
| Normalized EBITDA |
|
-66.50
+73.97%
|
-255.50
+39.67%
|
-423.51
+23.57%
|
-554.13
|
| Reconciled Depreciation |
|
17.70
-0.10%
|
17.71
-6.33%
|
18.91
+5.31%
|
17.96
|
| EBIT |
|
-132.00
+57.10%
|
-307.74
+28.45%
|
-430.08
+21.39%
|
-547.13
|
| Total Unusual Items |
|
-47.81
-38.49%
|
-34.52
-379.63%
|
12.35
-50.52%
|
24.95
|
| Total Unusual Items Excluding Goodwill |
|
-47.81
-38.49%
|
-34.52
-379.63%
|
12.35
-50.52%
|
24.95
|
| Net Income |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Pretax Income |
|
-212.65
+43.03%
|
-373.24
+21.28%
|
-474.14
+17.94%
|
-577.82
|
| Net Non Operating Interest Income Expense |
|
-44.88
-12.49%
|
-39.90
-217.79%
|
-12.55
+46.02%
|
-23.26
|
| Interest Expense Non Operating |
|
80.65
+23.12%
|
65.50
+48.65%
|
44.06
+43.62%
|
30.68
|
| Net Interest Income |
|
-44.88
-12.49%
|
-39.90
-217.79%
|
-12.55
+46.02%
|
-23.26
|
| Interest Expense |
|
80.65
+23.12%
|
65.50
+48.65%
|
44.06
+43.62%
|
30.68
|
| Interest Income Non Operating |
|
15.30
+6.55%
|
14.36
-14.81%
|
16.86
+127.00%
|
7.43
|
| Interest Income |
|
15.30
+6.55%
|
14.36
-14.81%
|
16.86
+127.00%
|
7.43
|
| Other Income Expense |
|
-31.50
+42.28%
|
-54.58
-802.35%
|
-6.05
-183.40%
|
7.25
|
| Gain On Sale Of Security |
|
-47.81
-38.49%
|
-34.52
-379.63%
|
12.35
-50.52%
|
24.95
|
| Tax Provision |
|
15.38
+217.63%
|
4.84
-33.68%
|
7.30
+35.82%
|
5.38
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-10.04
-38.49%
|
-7.25
-379.63%
|
2.59
-50.52%
|
5.24
|
| Net Income Including Noncontrolling Interests |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Net Income From Continuing Operation Net Minority Interest |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Net Income From Continuing And Discontinued Operation |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Net Income Continuous Operations |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Normalized Income |
|
-190.26
+45.76%
|
-350.81
+28.58%
|
-491.20
+18.53%
|
-602.90
|
| Net Income Common Stockholders |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Diluted EPS |
|
-3.76
+42.42%
|
-6.53
+23.63%
|
-8.55
+17.79%
|
-10.40
|
| Basic EPS |
|
-3.76
+42.42%
|
-6.53
+23.63%
|
-8.55
+17.79%
|
-10.40
|
| Basic Average Shares |
|
60.61
+4.69%
|
57.89
+0.00%
|
57.89
+3.25%
|
56.07
|
| Diluted Average Shares |
|
60.61
+4.69%
|
57.89
+0.00%
|
57.89
+3.25%
|
56.07
|
| Diluted NI Availto Com Stockholders |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Depreciation Amortization Depletion Income Statement |
|
9.82
+39.10%
|
7.06
+25.59%
|
5.62
+4.58%
|
5.38
|
| Depreciation And Amortization In Income Statement |
|
9.82
+39.10%
|
7.06
+25.59%
|
5.62
+4.58%
|
5.38
|
| Depreciation Income Statement |
|
—
|
6.60
+17.32%
|
5.62
+4.58%
|
5.38
|
| Earnings From Equity Interest |
|
16.31
+181.30%
|
-20.06
-9.05%
|
-18.39
-3.94%
|
-17.70
|
| Total Other Finance Cost |
|
-20.47
-81.98%
|
-11.25
+23.24%
|
-14.65
-439.06%
|
4.32
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,302.57
+10.43%
|
1,179.49
+42.87%
|
825.59
-24.24%
|
1,089.74
|
| Current Assets |
|
1,108.98
+4.54%
|
1,060.86
+50.96%
|
702.72
-23.90%
|
923.47
|
| Cash Cash Equivalents And Short Term Investments |
|
616.04
+10.10%
|
559.54
+40.08%
|
399.44
-45.69%
|
735.46
|
| Cash And Cash Equivalents |
|
616.04
+10.10%
|
559.54
+42.68%
|
392.16
-11.83%
|
444.77
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
7.28
-97.50%
|
290.69
|
| Receivables |
|
157.70
-11.13%
|
177.44
+218.15%
|
55.77
+117.64%
|
25.63
|
| Accounts Receivable |
|
141.33
-15.00%
|
166.28
+363.51%
|
35.87
+201.21%
|
11.91
|
| Other Receivables |
|
14.58
+55.38%
|
9.38
-50.86%
|
19.10
+48.81%
|
12.83
|
| Taxes Receivable |
|
1.78
+0.34%
|
1.77
+121.32%
|
0.80
-9.17%
|
0.88
|
| Inventory |
|
301.53
+2.00%
|
295.61
+41.49%
|
208.93
+59.89%
|
130.67
|
| Raw Materials |
|
19.08
+8.45%
|
17.60
-5.22%
|
18.57
+93.07%
|
9.62
|
| Work In Process |
|
253.49
+7.55%
|
235.69
+37.81%
|
171.03
+51.51%
|
112.89
|
| Finished Goods |
|
28.96
-31.59%
|
42.33
+118.90%
|
19.34
+136.60%
|
8.17
|
| Prepaid Assets |
|
33.72
+19.26%
|
28.27
-26.72%
|
38.58
+21.63%
|
31.72
|
| Total Non Current Assets |
|
193.59
+63.18%
|
118.63
-3.44%
|
122.87
-26.10%
|
166.27
|
| Net PPE |
|
146.48
+48.39%
|
98.71
-10.77%
|
110.63
-14.30%
|
129.09
|
| Gross PPE |
|
222.90
+21.56%
|
183.36
+0.66%
|
182.15
+3.65%
|
175.74
|
| Accumulated Depreciation |
|
-76.42
+9.72%
|
-84.65
-18.36%
|
-71.52
-53.31%
|
-46.65
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
22.77
+3.79%
|
21.93
-20.06%
|
27.44
+9.99%
|
24.94
|
| Other Properties |
|
193.09
+36.82%
|
141.13
+4.28%
|
135.34
+3.57%
|
130.67
|
| Leases |
|
7.05
-65.28%
|
20.30
+4.76%
|
19.38
-3.75%
|
20.13
|
| Goodwill And Other Intangible Assets |
|
3.71
-7.89%
|
4.03
-8.85%
|
4.42
-8.47%
|
4.83
|
| Goodwill |
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
|
| Other Intangible Assets |
|
0.21
-59.66%
|
0.53
-42.32%
|
0.92
-30.68%
|
1.33
|
| Investments And Advances |
|
32.53
+139.60%
|
13.57
+138.74%
|
5.69
-81.31%
|
30.42
|
| Long Term Equity Investment |
|
32.53
+139.60%
|
13.57
+138.74%
|
5.69
-75.20%
|
22.93
|
| Non Current Accounts Receivable |
|
10.87
+369.14%
|
2.32
+8.93%
|
2.13
+10.78%
|
1.92
|
| Total Liabilities Net Minority Interest |
|
1,465.39
+14.02%
|
1,285.20
+32.32%
|
971.28
+17.53%
|
826.39
|
| Current Liabilities |
|
1,069.39
+17.79%
|
907.86
+23.27%
|
736.51
+2.75%
|
716.78
|
| Payables And Accrued Expenses |
|
97.08
-0.54%
|
97.62
+0.78%
|
96.86
-9.07%
|
106.52
|
| Payables |
|
97.08
-0.54%
|
97.62
+0.78%
|
96.86
-9.07%
|
106.52
|
| Accounts Payable |
|
90.66
-5.95%
|
96.39
+1.93%
|
94.57
-6.40%
|
101.03
|
| Total Tax Payable |
|
6.43
+425.94%
|
1.22
-46.85%
|
2.30
-58.12%
|
5.49
|
| Income Tax Payable |
|
6.43
+425.94%
|
1.22
-46.85%
|
2.30
-58.12%
|
5.49
|
| Current Debt And Capital Lease Obligation |
|
486.53
-1.02%
|
491.54
+16.68%
|
421.27
+2.01%
|
412.98
|
| Current Debt |
|
486.53
-1.02%
|
491.54
+16.68%
|
421.27
+2.01%
|
412.98
|
| Other Current Borrowings |
|
486.53
-1.02%
|
491.54
+16.68%
|
421.27
+2.01%
|
412.98
|
| Current Capital Lease Obligation |
|
—
|
—
|
14.17
+2.78%
|
13.79
|
| Current Deferred Liabilities |
|
4.94
+428.21%
|
0.94
-20.95%
|
1.18
|
0.00
|
| Current Deferred Revenue |
|
4.94
+428.21%
|
0.94
-20.95%
|
1.18
|
0.00
|
| Other Current Liabilities |
|
314.44
+43.82%
|
218.63
+18.51%
|
184.47
-2.88%
|
189.94
|
| Total Non Current Liabilities Net Minority Interest |
|
396.00
+4.95%
|
377.34
+60.72%
|
234.78
+114.19%
|
109.61
|
| Long Term Debt And Capital Lease Obligation |
|
385.25
+5.53%
|
365.08
+63.72%
|
223.00
+133.75%
|
95.40
|
| Long Term Debt |
|
385.25
+5.53%
|
365.08
+63.72%
|
223.00
+133.75%
|
95.40
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
84.62
-11.30%
|
95.40
|
| Non Current Deferred Liabilities |
|
10.75
-12.33%
|
12.26
+4.07%
|
11.78
-17.13%
|
14.21
|
| Non Current Deferred Revenue |
|
1.12
-77.54%
|
5.00
-15.95%
|
5.95
-58.14%
|
14.21
|
| Non Current Deferred Taxes Liabilities |
|
9.62
+32.58%
|
7.26
+24.49%
|
5.83
|
0.00
|
| Stockholders Equity |
|
-162.82
-54.03%
|
-105.71
+27.45%
|
-145.70
-155.32%
|
263.35
|
| Common Stock Equity |
|
-162.82
-54.03%
|
-105.71
+27.45%
|
-145.70
-155.32%
|
263.35
|
| Capital Stock |
|
8.32
+2.12%
|
8.15
+5.16%
|
7.75
+0.96%
|
7.67
|
| Common Stock |
|
8.32
+2.12%
|
8.15
+5.16%
|
7.75
+0.96%
|
7.67
|
| Share Issued |
|
61.98
+2.12%
|
60.69
+5.17%
|
57.71
-0.96%
|
58.27
|
| Ordinary Shares Number |
|
61.38
+2.57%
|
59.84
+5.70%
|
56.61
-0.94%
|
57.15
|
| Treasury Shares Number |
|
0.60
-29.41%
|
0.85
-22.61%
|
1.09
-1.81%
|
1.11
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
-153.45
-160.02%
|
255.67
|
| Total Equity Gross Minority Interest |
|
-162.82
-54.03%
|
-105.71
+27.45%
|
-145.70
-155.32%
|
263.35
|
| Total Capitalization |
|
222.43
-14.24%
|
259.37
+235.55%
|
77.30
-78.45%
|
358.75
|
| Working Capital |
|
39.59
-74.12%
|
153.00
+552.82%
|
-33.79
-116.35%
|
206.69
|
| Invested Capital |
|
708.97
-5.59%
|
750.91
+50.61%
|
498.57
-35.40%
|
771.73
|
| Total Debt |
|
871.79
+1.77%
|
856.62
+32.96%
|
644.26
+26.73%
|
508.38
|
| Net Debt |
|
255.75
-13.91%
|
297.07
+17.84%
|
252.10
+296.32%
|
63.61
|
| Capital Lease Obligations |
|
—
|
—
|
98.79
-9.52%
|
109.19
|
| Net Tangible Assets |
|
-166.53
-51.76%
|
-109.73
+26.90%
|
-150.12
-158.07%
|
258.52
|
| Tangible Book Value |
|
-166.53
-51.76%
|
-109.73
+26.90%
|
-150.12
-158.07%
|
258.52
|
| Available For Sale Securities |
|
—
|
—
|
—
|
7.49
|
| Current Provisions |
|
166.40
+67.82%
|
99.15
+203.03%
|
32.72
+345.82%
|
7.34
|
| Derivative Product Liabilities |
|
—
|
—
|
143.30
-9.28%
|
157.95
|
| Investmentin Financial Assets |
|
—
|
0.00
|
0.00
-100.00%
|
7.49
|
| Investmentsin Associatesat Cost |
|
32.53
+139.60%
|
13.57
+138.74%
|
5.69
-75.20%
|
22.93
|
| Other Equity Interest |
|
-171.14
-50.32%
|
-113.86
+25.80%
|
-153.45
-160.02%
|
255.67
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
53.90
+117.60%
|
-306.20
+34.48%
|
-467.36
+5.72%
|
-495.70
|
| Cash Flow From Continuing Operating Activities |
|
53.90
+117.60%
|
-306.20
+34.48%
|
-467.36
+5.72%
|
-495.70
|
| Net Income From Continuing Operations |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Depreciation Amortization Depletion |
|
17.70
-0.10%
|
17.71
-6.33%
|
18.91
+5.31%
|
17.96
|
| Depreciation |
|
17.21
-0.24%
|
17.25
-6.41%
|
18.43
+5.22%
|
17.51
|
| Amortization Cash Flow |
|
0.49
+4.93%
|
0.47
-3.31%
|
0.48
+8.78%
|
0.44
|
| Depreciation And Amortization |
|
17.70
-0.10%
|
17.71
-6.33%
|
18.91
+5.31%
|
17.96
|
| Amortization Of Intangibles |
|
0.49
+4.93%
|
0.47
-3.31%
|
0.48
+8.78%
|
0.44
|
| Other Non Cash Items |
|
87.06
+83.86%
|
47.35
+2306.38%
|
-2.15
+49.40%
|
-4.24
|
| Stock Based Compensation |
|
116.17
+21.63%
|
95.51
+43.28%
|
66.66
+3.86%
|
64.18
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
6.14
|
| Asset Impairment Charge |
|
5.28
|
0.00
-100.00%
|
7.83
|
0.00
|
| Deferred Tax |
|
15.38
+217.63%
|
4.84
-33.68%
|
7.30
+35.82%
|
5.38
|
| Deferred Income Tax |
|
15.38
+217.63%
|
4.84
-33.68%
|
7.30
+35.82%
|
5.38
|
| Operating Gains Losses |
|
-16.31
-181.67%
|
19.97
+8.53%
|
18.40
+3.84%
|
17.72
|
| Gain Loss On Sale Of PPE |
|
0.00
+100.00%
|
-0.09
-1920.00%
|
0.01
-77.27%
|
0.02
|
| Change In Working Capital |
|
70.96
+166.22%
|
-107.16
-7.39%
|
-99.79
-700.08%
|
-12.47
|
| Change In Receivables |
|
15.59
+113.14%
|
-118.61
-261.90%
|
-32.77
-184.22%
|
-11.53
|
| Change In Inventory |
|
-5.92
+93.17%
|
-86.68
-10.76%
|
-78.26
-41.60%
|
-55.27
|
| Change In Prepaid Assets |
|
-6.05
-158.23%
|
10.39
+191.05%
|
-11.41
-78.08%
|
-6.41
|
| Change In Payables And Accrued Expense |
|
-10.37
-138.47%
|
26.96
+659.36%
|
3.55
-92.27%
|
45.94
|
| Change In Other Working Capital |
|
77.72
+27.88%
|
60.77
+218.06%
|
19.11
+29.16%
|
14.79
|
| Investing Cash Flow |
|
-8.48
-223.40%
|
6.88
-97.60%
|
286.47
+364.06%
|
61.73
|
| Cash Flow From Continuing Investing Activities |
|
-8.48
-223.40%
|
6.88
-97.60%
|
286.47
+364.06%
|
61.73
|
| Net PPE Purchase And Sale |
|
-8.48
-1678.83%
|
-0.48
+80.05%
|
-2.39
+51.74%
|
-4.95
|
| Purchase Of PPE |
|
-8.48
-494.60%
|
-1.43
+41.56%
|
-2.44
+83.15%
|
-14.49
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.95
+1762.75%
|
0.05
-99.47%
|
9.54
|
| Capital Expenditure |
|
-8.48
-494.60%
|
-1.43
+41.56%
|
-2.44
+83.15%
|
-14.49
|
| Capital Expenditure Reported |
|
—
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
7.35
-97.45%
|
288.87
+333.17%
|
66.69
|
| Purchase Of Investment |
|
—
|
0.00
|
0.00
+100.00%
|
-213.84
|
| Sale Of Investment |
|
0.00
-100.00%
|
7.35
-97.45%
|
288.87
+2.97%
|
280.53
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Financing Cash Flow |
|
36.33
-91.82%
|
443.93
+230.57%
|
134.29
-66.15%
|
396.77
|
| Cash Flow From Continuing Financing Activities |
|
36.33
-91.82%
|
443.93
+230.57%
|
134.29
-66.15%
|
396.77
|
| Net Issuance Payments Of Debt |
|
-21.96
-117.88%
|
122.79
-2.40%
|
125.82
-74.68%
|
496.93
|
| Issuance Of Debt |
|
0.00
-100.00%
|
134.16
-1.54%
|
136.26
-72.93%
|
503.28
|
| Repayment Of Debt |
|
-21.96
-93.21%
|
-11.37
-8.88%
|
-10.44
-64.22%
|
-6.36
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
134.16
-1.54%
|
136.26
-72.93%
|
503.28
|
| Long Term Debt Payments |
|
-21.96
-93.21%
|
-11.37
-8.88%
|
-10.44
-64.22%
|
-6.36
|
| Net Long Term Debt Issuance |
|
-21.96
-117.88%
|
122.79
-2.40%
|
125.82
-74.68%
|
496.93
|
| Net Common Stock Issuance |
|
-17.40
-105.61%
|
309.91
|
0.00
+100.00%
|
-105.31
|
| Common Stock Payments |
|
-17.40
|
0.00
|
0.00
+100.00%
|
-105.31
|
| Repurchase Of Capital Stock |
|
-17.40
|
0.00
|
0.00
+100.00%
|
-105.31
|
| Proceeds From Stock Option Exercised |
|
87.08
+185.37%
|
30.51
+196.66%
|
10.29
+99.61%
|
5.15
|
| Net Other Financing Charges |
|
-11.40
+40.93%
|
-19.29
-964.62%
|
-1.81
|
—
|
| Changes In Cash |
|
81.74
-43.47%
|
144.61
+410.35%
|
-46.59
-25.28%
|
-37.19
|
| Effect Of Exchange Rate Changes |
|
-25.24
-210.85%
|
22.77
+479.01%
|
-6.01
-116.83%
|
35.69
|
| Beginning Cash Position |
|
559.54
+42.68%
|
392.16
-11.83%
|
444.77
-0.34%
|
446.27
|
| End Cash Position |
|
616.04
+10.10%
|
559.54
+42.68%
|
392.16
-11.83%
|
444.77
|
| Free Cash Flow |
|
45.41
+114.76%
|
-307.62
+34.52%
|
-469.80
+7.92%
|
-510.19
|
| Common Stock Issuance |
|
0.00
-100.00%
|
309.91
|
0.00
|
0.00
|
| Earnings Losses From Equity Investments |
|
-16.31
-181.30%
|
20.06
+9.05%
|
18.39
+3.94%
|
17.70
|
| Interest Paid CFO |
|
-22.93
-50.84%
|
-15.21
+2.98%
|
-15.67
-68.62%
|
-9.29
|
| Interest Received CFO |
|
15.30
+6.46%
|
14.37
-15.69%
|
17.05
+106.12%
|
8.27
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
309.91
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
-6.68
-21.17%
|
-5.51
-23.42%
|
-4.47
-148766.67%
|
-0.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|